Mutant isocitrate dehydrogenase glioma lives on D-2-hydroxyglutarate. Vorasidenib blocks that enzyme and slows tumors, then they progress. Taglang and colleagues add a glucagon-like peptide-1 receptor agonist. In patient-derived and mouse mIDH glioma, the two drugs together make peroxynitrite, kill cells, shrink intracranial tumors, and extend survival beyond either drug alone.
Metal sites and redox
The GLP1R agonist turns on cAMP and protein kinase A, then nitric oxide synthase 1. Nitric oxide S-nitrosylates aconitase and ribonucleotide reductase. Aconitase is a mitochondrial [4Fe-4S] enzyme whose fourth iron is the substrate-binding site. Classic oxidative inactivation converts 4Fe to 3Fe. This paper does not report that conversion. It reports S-nitrosylation. Record that distinction. Vorasidenib, by lowering D-2HG, lets pyruvate dehydrogenase run and the authors measure more mitochondrial superoxide. Nitric oxide plus superoxide yield peroxynitrite (ONOO-), which they credit for lipid and DNA damage and apoptosis. Named couples in this story: NO, O2•-, ONOO-, and the NAD-linked PDH reaction. CuA, CuB, and respiratory Fe-S cores are not assigned as the superoxide source.
What was measured
Cellular synergy, cAMP-PKA, NOS1 dependence, NO, S-nitrosylation of aconitase and RNR, TCA and deoxyribonucleotide depletion, PDH relief, mitochondrial superoxide, peroxynitrite, lipid and DNA damage, apoptosis, and intracranial mouse pharmacodynamics, regression, and survival.
Caveats
Author mechanism until figures are inspected. GLP1R agonists are whole-body drugs. Superoxide site is not a named complex. Aconitase cluster nuclearity is inferred from the enzyme, not from spectroscopy.
What to do with it
Pair vorasidenib with GLP1R agonism as a redox combination: cytostatic nitrosylation plus superoxide, cytotoxic peroxynitrite only when both are present. The chemical test is whether a peroxynitrite scavenger or a NOS1 block undoes the survival gain.